SGLT2 inhibition in CKD: Discussing the key questions and evidence
EBAC-accredited E-LearningOnline-CME - This course consists of 3 lectures.
During this educational program, the effect of SGLT2i in diabetes patients with chronic kidney disease (CKD) is disscussed in three lectures.
This course consists of the following lectures:
- Outcomes of SGLT2i in Diabetic Kidney Disease: Is it all diabetes? - Prof. Rajiv Agarwal, MD - Indianapolis, IN, USA
- Underlying mechanisms of nephroprotective effects with SGLT2i in CKD - Paola Fioretto, MD – Padua, Italy
- The clinical landscape of managing patients with CKD: Where are we now and what can we expect? - Will Herrington, MD – Oxford, UK
After watching three videos on the effect of SGLT2i in diabetes patients with chronic kidney disease (CKD), the learner should be able to:
- Describe standard of care in patients with CKD and T2DM and novel therapeutic options to decrease progression of kidney disease
- Reproduce the design and outcome of the first kidney outcome trial with an SGLT2i
- Discuss potential mechanisms that can explain the nephroprotective effects of SGLT2i
- Recall kidney outcomes of SGLT2i outcome trials
- Describe patient groups that need to be included in future kidney trials
- Rajiv Agarwal, MD, MBBS, FASN is Professor of Medicine at Indiana University School of Medicine at Indianapolis, IN, USA.
- Paola Fioretto, MD, Associate Professor in Medicine at the University of Padova, Italy
- Will Herrington, MD, Honorary Consultant Nephrologist, University of Oxford, United Kingdom
This educational activity is designed for cardiologists in secondary care and other healthcare professionals with an interest in treating patients with diabetes and chronic kidney disease (CKD).
This online course is accredited by the European Board for Accreditation in Cardiology (EBAC) for 1 hour of external CME credit.
Through an agreement between the European Board for Accreditation in Cardiology and the American Medical Association, physicians may convert EBAC External CME credits to AMA PRA Category 1 Credits™. Information on the process to convert EBAC credit to AMA credit can be found on the AMA website. Other health care professionals may obtain from the AMA a certificate of having participated in an activity eligible for conversion of credit to AMA PRA Category 1 Credit™.
Funding for this educational program was provided by an unrestricted educational grant from Boehringer Ingelheim / Lilly.
This is available as accredited online CME for members. Click the button below to enroll:Enroll